Back to News
Market Impact: 0.35
Pharming Reports Positive Phase II Data For Leniolisib In Rare Genetic Immune Disorders
Source: Nasdaq
Healthcare & Biotech
Pharming Group N.V. announced positive topline results from a Phase II study evaluating leniolisib in patients with genetically identifiable primary immunodeficiencies associated with immune dysregulation linked to altered PI3Kδ signaling. The excerpt provides no efficacy, safety, or statistical figures, limiting assessment of the results’ magnitude.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
PHAR0.65
More News
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
- Supernus Pharmaceuticals stock hits 52-week low at 40.5 USD
- Liquidia shares surge 25% as settlement ends United Therapeutics litigation
- Top biotechnology stock pick from Guggenheim
- Needham raises Starling Oncology stock price target on growth outlook
- Stifel raises IQVIA stock price target on improving market backdrop
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More
- Alternative Data Due Diligence for Institutional Investors